Highest-materiality recent filing
NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review
MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.
Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
NWBO shareholders OK share increase to 2.6B, elect Pat Sarma
Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.
NWBO enters $5M convertible note with Yorkville for Sawston facility
Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.
Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M
Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.
Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility
Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.
Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity
Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.
Northwest Biotherapeutics secures $11M loan from Streeterville Capital
Loan of $11,005,000 from Streeterville Capital, maturity 22 months, repayments start Nov 2023.
NWBO enters $15M loan with Streeterville; conversion right tied to Phase III data
Net proceeds of $15M from Streeterville Capital, LLC; 22-month maturity, 8% interest, 10% OID.
The Board appointed Pat Sarma as a Class II director on March 18, 2024, and also appointed him to the Audit, Compensation, and Conflicts Committees of the Board.
Mr. Jerry Jasinowski retired from the Board of Directors of Northwest Biotherapeutics, Inc. on March 8, 2024, after more than a decade of service on the Board.
Max materiality 0.75 · Median 0.53 · Most common event debt